Cibc World Market Inc. Acquires 60,804 Shares of Medtronic PLC $MDT

Cibc World Market Inc. boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 17.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 419,242 shares of the medical technology company’s stock after buying an additional 60,804 shares during the period. Cibc World Market Inc.’s holdings in Medtronic were worth $40,272,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC boosted its stake in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the period. Board of the Pension Protection Fund bought a new position in Medtronic during the 4th quarter worth about $29,000. GoalVest Advisory LLC bought a new position in Medtronic during the 4th quarter worth about $29,000. Finally, Imprint Wealth LLC acquired a new stake in shares of Medtronic in the 3rd quarter valued at about $31,000. Institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 revenue and earnings estimates, driven by strong demand in cardiovascular devices, cardiac ablation, and medical-surgical products, which helped fuel the stock’s rebound.
• Positive Sentiment: The company raised its quarterly dividend to $0.72 per share, signaling confidence in cash generation and rewarding income-focused investors.
• Positive Sentiment: Management highlighted expanded Hugo robotic-assisted surgery filings and FDA activity, suggesting additional growth opportunities in surgical robotics. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system into general and gynecologic specialties in the United States
• Positive Sentiment: Several analysts maintained or upgraded bullish views, including BTIG’s upgrade to Buy and TD Cowen’s reiterated Buy, reinforcing optimism after the earnings beat. Wall Street May Be Mispricing Medtronic, Analyst Says
• Neutral Sentiment: Some analysts trimmed price targets while keeping neutral or hold ratings, including JPMorgan, Piper Sandler, Goldman Sachs, Baird, and Deutsche Bank, which reflects more cautious valuation views rather than a major change in the long-term story.
• Neutral Sentiment: Medtronic is also managing cardiovascular device recalls tied to sterile barrier concerns, creating an ongoing overhang even as newer product launches gain traction.
• Negative Sentiment: FY2027 EPS guidance came in slightly below the consensus estimate, and management noted tariff-related and margin pressure concerns, which may limit further upside. MDT Q4 Earnings Call Points to Another Year of Growth

Analyst Upgrades and Downgrades

MDT has been the subject of several recent research reports. Needham & Company LLC reduced their price objective on Medtronic from $120.00 to $101.00 and set a “buy” rating for the company in a research report on Wednesday. Daiwa Securities Group cut their target price on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Barclays upped their price target on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. TD Cowen reaffirmed a “buy” rating and set a $119.00 price target on shares of Medtronic in a research note on Thursday. Finally, The Goldman Sachs Group lowered their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday. Sixteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.70.

Medtronic Stock Performance

MDT opened at $81.95 on Friday. The business’s 50-day simple moving average is $81.58 and its 200 day simple moving average is $92.11. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market capitalization of $105.22 billion, a PE ratio of 21.97, a PEG ratio of 1.89 and a beta of 0.58.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The firm had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same quarter in the previous year, the firm earned $1.62 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.97 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. Medtronic’s dividend payout ratio is presently 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).